Post-earnings recap
Reported
Mon, Aug 5, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Arrowhead Pharmaceuticals is still facing challenges, particularly reflected in the EPS miss. The stock's 6.46% decline suggests investor disappointment, likely due to the lack of revenue data and forward guidance. Investors may be concerned about the company's path to profitability and future growth prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | -160.85% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the current market environment. They highlighted the importance of advancing their pipeline while remaining cautious about future performance.
Management expressed concerns about ongoing challenges in the market.
They emphasized the need for continued focus on product development.
There was no indication of a timeline for profitability.